MX363536B - Gel transdermico de progestina/estradiol. - Google Patents

Gel transdermico de progestina/estradiol.

Info

Publication number
MX363536B
MX363536B MX2012006755A MX2012006755A MX363536B MX 363536 B MX363536 B MX 363536B MX 2012006755 A MX2012006755 A MX 2012006755A MX 2012006755 A MX2012006755 A MX 2012006755A MX 363536 B MX363536 B MX 363536B
Authority
MX
Mexico
Prior art keywords
nestorone
estradiol
women
transdermal gel
estradiol transdermal
Prior art date
Application number
MX2012006755A
Other languages
English (en)
Other versions
MX2012006755A (es
Inventor
Regine Sitruk-Ware
Dario Norberto Ramon Carrara
Arnaud Grenier
Original Assignee
Antares Pharma Ipl Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antares Pharma Ipl Ag filed Critical Antares Pharma Ipl Ag
Publication of MX2012006755A publication Critical patent/MX2012006755A/es
Publication of MX363536B publication Critical patent/MX363536B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención describe composiciones y métodos para garantizar tanto en mujeres de edad fértil en las que garantiza también una anticoncepción con beneficios adicionales para la salud como en mujeres postmenopáusicas en las que ofrece una terapia hormonal con beneficios médicos adicionales tales como el potencial para un menor riesgo de trombosis. Las composiciones anteriormente mencionadas que comprenden NES como un potente agente progestacional y antiovulatorio sin efecto androgénico ni estrogénico ni glucocorticoide, y combinado con estradiol formulado para administración transdérmica no oral como dosis diarias específicas.
MX2012006755A 2009-12-17 2010-12-17 Gel transdermico de progestina/estradiol. MX363536B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28751409P 2009-12-17 2009-12-17
PCT/US2010/060941 WO2011084668A1 (en) 2009-12-17 2010-12-17 Nestorone®/estradiol transdermal gel

Publications (2)

Publication Number Publication Date
MX2012006755A MX2012006755A (es) 2012-11-23
MX363536B true MX363536B (es) 2019-03-27

Family

ID=43640394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006755A MX363536B (es) 2009-12-17 2010-12-17 Gel transdermico de progestina/estradiol.

Country Status (14)

Country Link
US (1) US9682087B2 (es)
EP (1) EP2512486B1 (es)
JP (1) JP6082249B2 (es)
KR (2) KR20120107492A (es)
CN (1) CN102753180A (es)
AU (1) AU2010339867B2 (es)
BR (1) BR112012014059B1 (es)
CA (1) CA2782075C (es)
ES (1) ES2641613T3 (es)
IN (1) IN2012DN04867A (es)
MX (1) MX363536B (es)
NZ (1) NZ600907A (es)
WO (1) WO2011084668A1 (es)
ZA (1) ZA201204267B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN102657661A (zh) * 2012-04-15 2012-09-12 温州医学院 Nestorone在制备治疗阿尔茨海默病的药物用途
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2648470C2 (ru) * 2016-03-03 2018-03-26 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации" (ГБОУ ВПО УГМУ Минздрава России) Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CA3213072A1 (en) * 2021-03-30 2022-10-06 David P. Kanios Transdermal systems having low dose estrogen and methods of making and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2083404C (en) 1990-06-01 2001-02-20 Alfred Moo-Young Therapeutically effective topical application of st1435
US5122382A (en) 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
US5198223A (en) * 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
JPH04342531A (ja) 1991-05-21 1992-11-30 Sekisui Chem Co Ltd 経皮吸収製剤
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
ES2669694T3 (es) * 2009-10-19 2018-05-28 The Population Council, Inc. Neuroprotección y reparación de mielina usando Nestorone®

Also Published As

Publication number Publication date
AU2010339867B2 (en) 2014-07-24
KR101928321B1 (ko) 2018-12-12
WO2011084668A1 (en) 2011-07-14
ZA201204267B (en) 2013-01-31
AU2010339867A1 (en) 2012-07-19
BR112012014059B1 (pt) 2020-03-10
EP2512486B1 (en) 2017-06-28
BR112012014059A8 (pt) 2017-12-26
KR20180084149A (ko) 2018-07-24
CN102753180A (zh) 2012-10-24
CA2782075C (en) 2015-06-30
JP6082249B2 (ja) 2017-02-15
BR112012014059A2 (pt) 2016-07-05
ES2641613T3 (es) 2017-11-10
IN2012DN04867A (es) 2015-09-25
US20130045953A1 (en) 2013-02-21
KR20120107492A (ko) 2012-10-02
US9682087B2 (en) 2017-06-20
NZ600907A (en) 2013-11-29
CA2782075A1 (en) 2011-07-14
MX2012006755A (es) 2012-11-23
EP2512486A1 (en) 2012-10-24
JP2013514984A (ja) 2013-05-02

Similar Documents

Publication Publication Date Title
MX363536B (es) Gel transdermico de progestina/estradiol.
NZ615430A (en) Method for on-demand contraception
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
PL2131847T3 (pl) Lek zawierający przynajmniej jeden gestagen
MX347890B (es) Neuroproteccion y reparacion de melina usando progestina.
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
MY161549A (en) Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
WO2010033188A3 (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
MX2012012026A (es) Formas de dosificacion solidas orales con dosis muy bajas para la hrt.
AU2012293593A8 (en) Use of estetrol as emergency contraceptive
NZ600759A (en) Use of an oleogel containing triterpene for healing wounds
MX338290B (es) Tratamiento de enfermedad de alzheimer, perdida de cognición, perdida de memoria y demencia con precursores de esteroides sexuales en conbinación con moduladores selectivos del receptor de estrógenos.
GB2479337A (en) Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
TW200726473A (en) Compositions and methods for treatment of cycle-related symptoms
PH12015500062A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
SE0400346D0 (sv) Steroids for cancer treatment
ZA201908404B (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
MY172530A (en) Method for treating gynecological diseases
NZ627242A (en) Transdermal hormone delivery
ZA202303273B (en) New modified release oral contraceptive composition
TN2010000007A1 (en) 8-beta- substituted estratrienes as selectively active estrogens
TW200612962A (en) Estriol and estetrol prodrugs
MX2021006426A (es) Sistema de suministro de farmaco para combinaciones de estrogeno de dosis ultra-baja y metodos y usos del mismo.
Frey Ethinylestradiol/drospirenone/norelgestromin